
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Vitamin D deficiency medical therapy
Introduction
Overview
Overview
The mainstay of therapy for vitamin D deficiency is vitamin D, either vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol). Vitamin D supplements could be used as a daily loading regimen followed by the maintenance. The alternative regimen is high weekly dose (stoss therapy) and maintenance therapy.
Medical therapy
Medical therapy
There are two major forms of vitamin D; ergocalciferol (vitamin D2), cholecalciferol (vitamin D3). Both of them are commonly used. However, a systematic review and meta-analysis of Tripkovic L et al. in 2011, indicated that vitamin D3 compared to vitamin D2 is more effective to raise the serum level of 25OHD and is preferred for treatment and prevention of vitamin D deficiency.[1]
- Endocrine Society published a clinical practice guideline for the treatment of vitamin D deficiency to reach and sustain a serum 25(OH)D level of 30 ng/ml.[2]
| Age | Loading dose | Alternative dose | Maintenance dose |
|---|---|---|---|
| 0-1 y | 2000 IU/d orally for 6 weeks | 50,000 IU/w orally for 6 weeks | 400-1000 IU/d |
| 1-18 y | 2000 IU/d orally for 6 weeks | 50,000 IU/w orally for 6 weeks | 600-1000 IU/d |
| Adults | 50,000 IU/w orally for 8 weeks | 6000 IU/d orally for 6 weeks | 1500–2000 IU/d |
| Nursing home residents | 50,000 IU/three times per week for 1 month | 100,000 IU of vitamin D every 4 months | |
| High risk patients* | 6000-10,000 IU/d | 3000–6000 IU/d |
- High risk patients include African American, obese, patients with malabsorption syndromes and who are on anticonvulsants.
- The American Academy of Pediatrics (AAP) recommends an initial phase of treatment with high dose of vitamin D for 2-3 months to treat vitamin D deficiency rickets. The recommended dose is 1000 IU/d in neonates, 1000-5000 IU/d in infants, and 5000 IU/d for children over 1-year-old. After raising the serum 25 OHD levels to 30 ng/ml, a maintenance dose of 400 IU/d is required for all age groups. Higher maintenance dose (800 IU/d) might be needed in at risk groups.[3][4]
- An alternative strategy for treatment, also known as stoss therapy, is a single dose therapy in patients over 1 month old. 100,000 – 600,000 IU of ergocalciferol orally single dose followed by maintenance therapy is recommended, especially in noncompliant patients.[5]
A more recent randomized controlled trial showed that, among white women with vitamin D insufficiency and deficiency (levels 13 to 50 nmol/L;5 to 20 ng/mL ), a dose of 600 to 800 IU per day of vitamin D3 will raise the level above Institute of Medicine recommendations (20 ng/mL or 50 nmol/L) in 97% of women.[6]
Regarding choice of preparation, D3 (cholecalciferol) may be more effective than D2 (ergocalciferol).[7]
Obese patients need more vitamin D to raise their level.[8]
Does higher than at least 800 IU daily may be best for the prevention of fractures.[9]
One option is a combination pill. Either the size below once per day, or a half size twice per day.
- Elemental calcium 1200 mg, daily
- Vitamin D3 800 international units (20 micrograms), daily
Special circumstances
- Patients on anticonvulsant drugs are at risk of vitamin D deficiency. If osteopenia occurs, treatment with 2000-4000 IU/d must be started. In case of osteomalacia, a larger dose of vitamin D, 5000-15000 IU/d is required.[10]
References
References
- ↑ Tripkovic, L.; Lambert, H.; Hart, K.; Smith, C. P.; Bucca, G.; Penson, S.; Chope, G.; Hypponen, E.; Berry, J.; Vieth, R.; Lanham-New, S. (2012). “Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis”. American Journal of Clinical Nutrition. 95 (6): 1357–1364. doi:10.3945/ajcn.111.031070. ISSN 0002-9165.
- ↑ Holick, Michael F.; Binkley, Neil C.; Bischoff-Ferrari, Heike A.; Gordon, Catherine M.; Hanley, David A.; Heaney, Robert P.; Murad, M. Hassan; Weaver, Connie M. (2011). “Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline”. The Journal of Clinical Endocrinology & Metabolism. 96 (7): 1911–1930. doi:10.1210/jc.2011-0385. ISSN 0021-972X.
- ↑ Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008). “Vitamin D deficiency in children and its management: review of current knowledge and recommendations”. Pediatrics. 122 (2): 398–417. doi:10.1542/peds.2007-1894. PMID 18676559.
- ↑ Lee, Ji Yeon; So, Tsz-Yin; Thackray, Jennifer (2013). “A Review on Vitamin D Deficiency Treatment in Pediatric Patients”. The Journal of Pediatric Pharmacology and Therapeutics. 18 (4): 277–291. doi:10.5863/1551-6776-18.4.277. ISSN 1551-6776.
- ↑ Shah BR, Finberg L (1994). “Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method”. J. Pediatr. 125 (3): 487–90. PMID 8071764.
- ↑ Gallagher JC, Sai A, Templin T, Smith L (2012). “Dose response to vitamin d supplementation in postmenopausal women: a randomized trial”. Ann Intern Med. 156 (6): 425–37. doi:10.1059/0003-4819-156-6-201203200-00005. PMID 22431675.
- ↑ Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J (2013). “Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial”. J Clin Endocrinol Metab. 98 (11): 4339–45. doi:10.1210/jc.2012-4287. PMID 24001747.
- ↑ Drincic A, Fuller E, Heaney RP, Armas LA (2013). “25-hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults”. J Clin Endocrinol Metab. 98 (12): 4845–51. doi:10.1210/jc.2012-4103. PMID 24037880.
- ↑ Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA; et al. (2012). “A pooled analysis of vitamin D dose requirements for fracture prevention”. N Engl J Med. 367 (1): 40–9. doi:10.1056/NEJMoa1109617. PMID 22762317.
- ↑ Drezner MK (2004). “Treatment of anticonvulsant drug-induced bone disease”. Epilepsy Behav. 5 Suppl 2: S41–7. doi:10.1016/j.yebeh.2003.11.028. PMID 15123011.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
